Top

Published in:

01-11-2013 | Preclinical study

Tumor immune subtypes distinguish tumor subclasses with clinical implications in breast cancer patients

Authors: Esther M. de Kruijf, Charla C. Engels, Willemien van de Water, Esther Bastiaannet, Vincent T. H. B. M. Smit, Cornelis J. H. van de Velde, Gerrit Jan Liefers, Peter J. K. Kuppen

Published in: Breast Cancer Research and Treatment | Issue 2/2013

Abstract

There is strong evidence that the host’s cellular immune response is linked to tumor progression, however its impact on patient outcome in breast cancer is poorly understood. The purpose of this study is to define tumor immune subtypes, focusing on cellular immune responses and investigate their prognostic effect in breast cancer patients. Our training (n = 440) and validation cohort (n = 382) consisted of all early breast cancer patients primarily treated with surgery in our center between 1985 and 1996. Tumor tissue sections were immunohistochemically stained for CD8 (CTL) and PEN5 (NK cells). Tumor expression of classical and non-classical human leukocyte antigen class I, and tumor-infiltrating Tregs were previously determined. Tumor immune subtypes were constructed based on quantification of these markers and biological rationale. High, intermediate, and low immune susceptible tumor immune subtypes were found, respectively, in 16, 63, and 20 % of patients in the training cohort and 16, 71, and 13 % in the validation cohort. The subtypes showed to be statistically significant prognostic in multivariate analyses for relapse free period (RFP) [p < 0.0001, intermediate versus high: hazard ratio (HR) 1.95; low versus high HR 2.98] and relative survival (RS) (p = 0.006, intermediate versus high HR 3.84; low versus high: HR 4.26). Validation of these outcome analyses confirmed the independent prognostic associations: RFP (p = 0.025) and RS (p = 0.040). The tumor immune subtypes that we present represent a prognostic profile with solid underlying biological rationale and with high discriminative power confirmed in an independent validation cohort. Our results emphasize the importance of tumor immune surveillance in the control of tumor development and, therefore, in determining patient prognosis. Tumor immune subtype profiling is promising for prognosis prediction and the achievement of tailored treatment for breast cancer patients.

Available only for authorised users

Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRef

Goldhirsch A, Wood WC, Gelber RD et al (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18:1133–1144PubMedCrossRef

Zitvogel L, Tesniere A, Kroemer G (2006) Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6:715–727PubMedCrossRef

Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329–360PubMedCrossRef

Algarra I, Garcia-Lora A, Cabrera T et al (2004) The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother 53:904–910PubMedCrossRef

Wischhusen J, Waschbisch A, Wiendl H (2007) Immune-refractory cancers and their little helpers: an extended role for immunetolerogenic MHC molecules HLA-G and HLA-E? Semin Cancer Biol 17:459–468PubMedCrossRef

Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol 3:999–1005PubMedCrossRef

Marin R, Ruiz-Cabello F, Pedrinaci S et al (2003) Analysis of HLA-E expression in human tumors. Immunogenetics 54:767–775PubMed

Cerwenka A, Baron JL, Lanier LL (2001) Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci USA 98:11521–11526PubMedCrossRef

10.

Liu F, Lang R, Zhao J et al (2011) CD8(+) cytotoxic T cell and FOXP3(+) regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat 130(2):645–655PubMedCrossRef

11.

Mahmoud SM, Paish EC, Powe DG et al (2011) Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 29:1949–1955PubMedCrossRef

12.

de Kruijf EM, Sajet A, van Nes JG et al (2010) HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients. J Immunol 185:7452–7459PubMedCrossRef

13.

Kleinberg L, Florenes VA, Skrede M et al (2006) Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. Virchows Arch 449:31–39PubMedCrossRef

14.

Lefebvre S, Antoine M, Uzan S et al (2002) Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J Pathol 196:266–274PubMedCrossRef

15.

Bates GJ, Fox SB, Han C et al (2006) Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24:5373–5380PubMedCrossRef

16.

de Kruijf EM, van Nes JG, Sajet A et al (2010) The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer. Clin Cancer Res 16:1272–1280PubMedCrossRef

17.

Ladoire S, Arnould L, Apetoh L et al (2008) Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin Cancer Res 14:2413–2420PubMedCrossRef

18.

Galon J, Costes A, Sanchez-Cabo F et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960–1964PubMedCrossRef

19.

van Nes JG, de Kruijf EM, Faratian D et al (2010) COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients. Breast Cancer Res Treat 125(3):671–685PubMed

20.

Ghiringhelli F, Menard C, Terme M et al (2005) CD4+ CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 202:1075–1085PubMedCrossRef

21.

DeNardo DG, Brennan DJ, Rexhepaj E et al (2011) Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 1:54–67PubMedCrossRef

22.

Matkowski R, Gisterek I, Halon A et al (2009) The prognostic role of tumor-infiltrating CD4 and CD8 T lymphocytes in breast cancer. Anticancer Res 29:2445–2451PubMed

23.

Gobert M, Treilleux I, Driss-Vermare N et al (2009) Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 69:2000–2009PubMedCrossRef

24.

Madjd Z, Spendlove I, Pinder SE et al (2005) Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer 117:248–255PubMedCrossRef

25.

Gudmundsdottir I, Gunnlaugur JJ, Sigurdsson H et al (2000) Altered expression of HLA class I antigens in breast cancer: association with prognosis. Int J Cancer 89:500–505PubMedCrossRef

26.

Redondo M, Garcia J, Villar E et al (2003) Major histocompatibility complex status in breast carcinogenesis and relationship to apoptosis. Hum Pathol 34:1283–1289PubMedCrossRef

27.

Menon AG, Janssen-Van Rhijn CM, Morreau H et al (2004) Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab Invest 84:493–501PubMedCrossRef

28.

Harris L, Fritsche H, Mennel R et al (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287–5312PubMedCrossRef

29.

Michiels S, Koscielny S, Hill C (2005) Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 365:488–492PubMedCrossRef

30.

van de Vijver MJ, He YD, van’t Veer LJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009PubMedCrossRef

31.

Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360:790–800PubMedCrossRef

32.

McShane LM, Altman DG, Sauerbrei W et al (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229–235PubMedCrossRef

Title: Tumor immune subtypes distinguish tumor subclasses with clinical implications in breast cancer patients
Authors: Esther M. de Kruijf
Charla C. Engels
Willemien van de Water
Esther Bastiaannet
Vincent T. H. B. M. Smit
Cornelis J. H. van de Velde
Gerrit Jan Liefers
Peter J. K. Kuppen
Publication date: 01-11-2013
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2013
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-013-2752-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2013

Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43

Response to neoadjuvant chemotherapy in ductal compared to lobular carcinoma of the breast: a meta-analysis of published trials including 1,764 lobular breast cancer

Genomic profiling of histological special types of breast cancer

Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes

Expression and clinical significance of carcinoembryonic antigen-related cell adhesion molecule 6 in breast cancers

Margin negative, breast conserving resection: adequate for benign phyllodes tumors, but inadequate therapy for borderline and malignant phyllodes tumors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer